Перейти к контенту
Main image
Печать
Pristimerin 1PC X 5MG
Кат. №: 530070-5MG
Производитель: Sigma-Aldrich
Кол-во:
Фасовка:
Цена по запросу
Товар оформляется под заказ
Печать
Pristimerin 1PC X 5MG
Main image
Кат. №: 530070-5MG
Производитель: Sigma-Aldrich
Кол-во:
Фасовка:
Цена по запросу
Товар оформляется под заказ
Main image
Печать
Pristimerin 1PC X 5MG
Кат. №: 530070-5MG
Производитель: Sigma-Aldrich
Кол-во:
Фасовка:
Цена по запросу
Товар оформляется под заказ
Description General description A cell-permeable plant dienone-phenolic triterpenoid, naturally isolated from tripterygium wilfordii, whose inhibitory activities against proteasome chymotrypsin subunit (IC50 = 2.2 and 3.0 µM against purified rabbit 20S and human 26S proteasome, respectively) and cellular NF-κB pathway/IKK activation most likely account for its reported anticancer efficacy both in vitro (IC50 ≤610 nM in A549, K562, KBM5, MCF-7, MDA-MB-231, HepG2, and primary human leukemia cell cultures) and in mice in vivo (1 to 2.5 mg/kg/day, s.c.), including imatinib/STI571-resistant cancer cells harboring Bcr-Abl T315I mutation. Also reported to inhibit the activity of monoacylglycerol lipase (MGL), the enzyme that hydrolyzes and deactivates the cannabionoid receptor ligand 2-Arachidonoyl-sn-glycerol (2-AG), in a reversible manner with high potency (IC50 = 93 nM). Packaging 5 mg in Plastic ampoule Packaged under inert gas Warning Toxicity: Standard Handling (A) Other Notes Lu, Z., et al. 2010. Mol. Cancer9, 112. King, A.R., et al. 2009. Chem. Biol.16, 1045. Tiedemann, R.E., et al. 2009. Blood113, 4027. Yang, H., et al. 2008. J. Cell. Biochem.103, 234. Wu, C.C., et al. 2005. Mol. Cancer Ther.4, 1277.
Quality Level
100 assay
Дорогой клиент, на сайте внедрена нейросеть для сбора информации о товаре. Это может привести к незначительным расхождениям в характеристиках продукции.
Description General description A cell-permeable plant dienone-phenolic triterpenoid, naturally isolated from tripterygium wilfordii, whose inhibitory activities against proteasome chymotrypsin subunit (IC50 = 2.2 and 3.0 µM against purified rabbit 20S and human 26S proteasome, respectively) and cellular NF-κB pathway/IKK activation most likely account for its reported anticancer efficacy both in vitro (IC50 ≤610 nM in A549, K562, KBM5, MCF-7, MDA-MB-231, HepG2, and primary human leukemia cell cultures) and in mice in vivo (1 to 2.5 mg/kg/day, s.c.), including imatinib/STI571-resistant cancer cells harboring Bcr-Abl T315I mutation. Also reported to inhibit the activity of monoacylglycerol lipase (MGL), the enzyme that hydrolyzes and deactivates the cannabionoid receptor ligand 2-Arachidonoyl-sn-glycerol (2-AG), in a reversible manner with high potency (IC50 = 93 nM). Packaging 5 mg in Plastic ampoule Packaged under inert gas Warning Toxicity: Standard Handling (A) Other Notes Lu, Z., et al. 2010. Mol. Cancer9, 112. King, A.R., et al. 2009. Chem. Biol.16, 1045. Tiedemann, R.E., et al. 2009. Blood113, 4027. Yang, H., et al. 2008. J. Cell. Biochem.103, 234. Wu, C.C., et al. 2005. Mol. Cancer Ther.4, 1277.
Quality Level
100 assay
Дорогой клиент, на сайте внедрена нейросеть для сбора информации о товаре. Это может привести к незначительным расхождениям в характеристиках продукции.